title: Modulatory role of glutathione on mu-opioid, substance P/neurokinin-1, and kainic acid receptor binding sites.
abstract: Reduced glutathione (L-gamma-glutamyl-L-cysteinylglycine; GSH) is an endogenous tripeptide involved in the formation and maintenance of protein thiol groups as well as in various detoxification reactions. Because multiple receptor types contain thiol groups or disulfide bridges, effects of GSH treatments on mu-opioid, neurokinin-1/substance P, and kainic acid receptor binding sites were investigated and compared with those produced by dithiothreitol (DTT), a potent synthetic reducing agent. GSH inhibited binding more potently than did DTT at all three receptor types in porcine striatal membrane homogenates as well as in CHAPS-solubilized preparations of the mu and neurokinin-1 sites. GSH-induced inhibitory effects were associated with decreases in maximal binding capacity (Bmax) without significant alteration in apparent affinity (KD). Cysteine, the functional moiety of GSH, mimicked GSH effects albeit with lower potencies, whereas oxidized glutathione had no effects at similar concentrations. In CHAPS-solubilized preparations, the combination of low concentrations of GSH and guanylylimidodiphosphate markedly decreased the Bmax values of the binding of [3H][D-Ala2,Gly-ol5]enkephalin and [3H]substance P. This GSH-mediated mechanism may be important to prevent cell overstimulation by accelerating receptor uncoupling, desensitization, and/or internalization. This is in keeping with purported roles of GSH related to the maintenance of cellular integrity.
authors.affiliation: Department of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
authors.forename: Y F
authors.initials: YF
authors.lastname: Liu
authors.forename: R
authors.initials: R
authors.lastname: Quirion
mesh_terms: D000818:Animals; D001665:Binding Sites / Q000187:drug effects; D002793:Cholic Acids / Q000494:pharmacology; D003902:Detergents; D004229:Dithiothreitol / Q000494:pharmacology; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins / Q000378:metabolism; D005978:Glutathione / Q000494:pharmacology / Q000502:physiology*; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D007608:Kainic Acid / Q000378:metabolism; D018092:Kainic Acid Receptors; D018040:Receptors, Neurokinin-1; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D011957:Receptors, Opioid / Q000378:metabolism*; D017450:Receptors, Opioid, mu; D012995:Solubility; D013373:Substance P / Q000378:metabolism; D013552:Swine
chemical_list: D002793:Cholic Acids; D003902:Detergents; D004229:Dithiothreitol; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004745:Enkephalins; D005978:Glutathione; D006165:Guanylyl Imidodiphosphate; D007608:Kainic Acid; D018092:Kainic Acid Receptors; D018040:Receptors, Neurokinin-1; D017981:Receptors, Neurotransmitter; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D013373:Substance P; C028213:3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate